Biotech Financing & IPOs 2 articles

Biotech Financing & IPOs covers how biotechnology companies raise capital through private rounds, public offerings, follow-ons, private placements and other financing structures. Terms, investor participation, use of proceeds and timing are interpreted in relation to pipeline maturity and development needs. The section differs from Cash Runway & Dilution by focusing on the financing transaction itself, and from market updates by examining capital formation rather than sector trading conditions.

Biotech Companies & Pipelines

October 2, 2026, 10:05 AM · 4 mins read

Biotech Investors Demand Proof as Funding Surges for Select Companies

Biotech venture funding is back near record highs, but only startups with strict capital discipline and proven science are getting money. CERo Therapeutics CEO Chris Ehrlich explains why capital strategy now matters as much as innovation.

Clinical Trials & Evidence

October 1, 2026, 11:06 PM · 3 mins read

Aclipse Therapeutics eyes Cypress BioPharma buyout, targets dual Phase 2 push in kidney disease

Aclipse Therapeutics has locked in an option to acquire Cypress BioPharma. The company plans to expand its M107 drug into childhood nephrotic syndrome and launch two Phase 2 trials, while raising Series B funds.